Flamingo Therapeutics
Biotechnology ResearchView the employees at
Flamingo Therapeutics-
Veronica Finisguerra Postdoc Fellow at Ludwig Institute for Cancer Research, Brussels, de Duve Institute, UCL
-
Brussels Metropolitan Area
-
Rising Star
Marie-Aline Neveu Senior Scientist specialized in Oncology and in vivo pharmacology | Pharmacist | PhD-
Top 5%
Mark Gidjunis VP Finance - Corporate Controller at Flamingo-
Cherry Hill, New Jersey, United States
-
Rising Star
Stephane van Rooijen CEO at Flamingo Therapeutics-
Belgium
-
Top 5%
Tiziana Girardi Associate Director of Drug Discovery at Flamingo Therapeutics-
Leuven, Flemish Region, Belgium
-
Rising Star
Overview
Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in combination with pembrolizumab, in patients with head and neck squamous cell carcinoma (HNSCC). Flamingo has an alliance with Ionis Pharmaceuticals and is supported by well-known biotechnology investors including Andera Partners, Bpifrance Large Venture, Bpifrance through its FABS and Fonds Biothérapies Innovantes et Maladies Rares funds, Eurazeo - Kurma Partners, Perceptive Advisors, PMV, Pontifax, Sphera, funds managed by Tekla Capital Management LLC and VIB.
-